The final supplemental Environmental Impact Statement (EIS) on SHINE Medical Technology, LLC’s, application for a license to operate a medical isotope production facility in Janesville, Wisconsin, is now completed.

Nuclear Regulatory Commission (NRC) staff weighed the facility’s environmental, economic, technical and other benefits against environmental and other impacts, and recommended that, unless safety issues mandate otherwise, the license should be issued.

The agency will consider the EIS and the Final Safety Evaluation Report for the SHINE application in deciding whether to issue the license.

SHINE filed the application on July 17, 2019, seeking the license to operate the facility, currently under construction in Janesville.

The facility would create molybdenum-99, which subsequently produces technetium-99m, an isotope used in over 30 different diagnostic medical imaging procedures. Information on the operating license review, with proprietary details removed, is available on the NRC website.

Pin It on Pinterest

Share This